Diligence memo · auto-generated · as of July 3, 2026
AimMax Therapeutics, Inc.
AimMax Therapeutics, Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
AimMax Therapeutics, Inc. operates in Pharma, based in CHAPEL HILL.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
AimMax Therapeutics, Inc. has raised $200K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $200K on 2017-04-14.
Most recent recorded round closed around 2017-04-14.
Valuation (modeled)modeled
Provath models AimMax Therapeutics, Inc. at approximately $9.5M (range $112K–$107M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.67× the median modeled value of Pre-Seed Pharma companies in 2016–2018 (20 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 9.2 yr ago; this sector typically re-raises about every 16 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 22% of Pharma peers (310 compared).
Modeled value ranks above 34% of those peers.
Closest niche peers: vivo-TIL Therapeutics, Inc, JSK Therapeutics, Inc., Kyto Biopharma Inc, Manzara Therapeutics, Inc., Mirata BioPharma, LLC.
Peoplefiled
1 named person on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.